Utah Medical Products, Inc.: UTMD Announces Self-Tender for 20% of Its Shares

Utah Medical Products (UTMD) announced a self-tender offer to repurchase up to 650,000 shares, or 20% of its outstanding shares, at $75.00 per share. This price is 17% higher than the 12-month average and 21% higher than the 2-year average. The offer, starting September 22, is not conditioned on a minimum number of shares. The company's board approved the offer but did not recommend it to stockholders.

Original reporting
Published Sep 15, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UTMD
Bullish
high confidence
Mentioned
$UTMD
Relevance
6/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$UTMDBullishMed
01

Why it matters

The self‑tender offers a 17% premium to the 12‑month average price, likely providing short‑term support to the stock.

02

Market read

A micro‑cap buyback at a premium is a notable catalyst for the stock, offering a clear decision point for shareholders.

03

What to watch

Potential dilution of cash reserves and limited free cash flow to sustain future operations.

Relevance 6/10Novelty 6/10Timing: tender offer opens Sep 22, expires Oct 7

Background

Utah Medical Products develops disposable and reusable specialty medical devices for women's health and neonatal care.

Company-level read

Ticker impact

$UTMDBullishHigh confidence
Context

Utah Medical Products announced a self‑tender offer to repurchase up to 20% of its shares at $75 per share.

Expected impact

Potential short‑term price uplift as investors price in the premium buyback.

Evidence & confidence

Buybacks at a premium are uncommon for micro‑caps and signal confidence, likely attracting buying interest.

Market effects

May signal confidence in the medical device sector, potentially benefiting peers.

Limited to US micro‑cap market; no broader regional effect.

Minimal global impact beyond niche investors.

Counterpoint

The premium could be a red flag if management is overvaluing the stock to prop up a weak business.

Key entities

  • Kevin Cornwell

    Chairman & CEO of Utah Medical Products, quoted on the buyback rationale.

Related articles

$UTMDHigh

UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 Contact: Brian Koopman (801) 566-1200 October 22, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports third quarter (3Q) and first nine months (9M) of calend

$UTMDHigh

Utah Medical Products, Inc. Commences Tender Offer

Utah Medical Products (UTMD) offers to buy up to 650,000 shares at $75 each, a 17% premium over the 12-month average. The tender offer, approved by the board, aims to provide liquidity. UTMD's H1 2026 sales and profits declined 12% and 13% YoY, with recent EBITDA at $15.7M. CEO Cornwell believes shares are undervalued, citing industry multiples. The offer expires Oct 7 unless extended.

$UTMDMed

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026

UTAH MEDICAL PRODUCTS INC (UTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 utmd_ex99z1.htm EXHIBIT 99.1 EXHIBIT 99.1 UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2026 Contact: Brian Koopman (801) 566-1200 July 23, 2026 Salt Lake City, Utah – Utah Medical Products, Inc. [Nasdaq: UTMD] reports second calendar qua